Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge

被引:46
|
作者
Tricoci, P
Roe, MT
Mulgund, J
Newby, LK
Smith, SC
Pollack, CV
Fintel, DJ
Cannon, CP
Bhatt, DL
Gibler, WB
Ohman, EM
Peterson, ED
Harrington, RA
机构
[1] Duke Univ, Clin Res Inst, Durham, NC 27705 USA
[2] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA
[3] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[4] Penn Hosp, Philadelphia, PA 19107 USA
[5] Northwestern Univ, Sch Med, Chicago, IL 60611 USA
[6] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
[7] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[8] Univ Cincinnati, Sch Med, Cincinnati, OH USA
关键词
D O I
10.1001/archinte.166.7.806
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clopidogrel added to aspirin improved out-comes after hospitalization in patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, regardless of in-hospital treatment approach. The American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for treating NSTE ACS thus recommend prescribing clopidogrel plus aspirin at discharge for all patients, not just for those undergoing percutaneous coronary intervention (PCI). Methods: We studied 61052 patients with high-risk NSTE ACS (defined as the presence of positive cardiac markers and/or ischemic ST-segment changes) from January 2002 through December 2003 at 461 US hospitals participating in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Quality Improvement Initiative. We evaluated temporal trends of clopidogrel use at discharge since the ACC/AHA 2002 Guidelines update and examined variables associated with clopidogrel use in patients who did not undergo PCI. Results: A total of 34319 patients (56.2%) received clopidogrel when they were discharged from the hospital. Among patients who did not undergo PCI, variables associated with receiving clopidogrel at discharge included prior PCI, coronary artery bypass grafting (CABG), stroke, or myocardial infarction; hypercholesterolemia; elevated cardiac markers; and cardiology inpatient care. By late 2003, 96.3% of patients who underwent PCI received clopidogrel at discharge, compared with 42.8% of patients who did not undergo cardiac catheterization and 23.5% of the patients who underwent CABG, although clopidogrel prescription at discharge increased in each of these treatment groups from 2002 to 2003. Conclusion: Since release of the ACC/AHA Guidelines recommendations for treatment of NSTE ACS, prescription of clopidogrel at hospital discharge in patients with NSTE ACS who are treated with medical therapy alone and in those who undergo CABG has increased, but most of these patients still do not receive clopidogrel at discharge.
引用
收藏
页码:806 / 811
页数:6
相关论文
共 50 条
  • [31] Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes
    Bertrand, Michel E.
    Van Belle, Eric
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2006, 8 (0G) : G59 - G63
  • [32] Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes?
    Charles Antzelevitch
    Nature Clinical Practice Cardiovascular Medicine, 2008, 5 : 248 - 249
  • [33] Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes
    Boden, WE
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (12B): : 42M - 47M
  • [34] Early invasive strategy in diabetic patients with non-ST-segment elevation acute coronary syndromes
    Baeza Roman, Anna
    Latour Perez, Jaime
    de Miguel Balsa, Eva
    Pino Izquierdo, Karel
    Coves Orts, Francisco Javier
    Garcia Ochando, Luis
    de la Torre Fernandez, Maria Jose
    MEDICINA CLINICA, 2014, 142 (10): : 427 - 431
  • [35] Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
    Rao, Sunil V.
    Eikelboom, John A.
    Granger, Christopher B.
    Harrington, Robert A.
    Califf, Robert M.
    Bassand, Jean-Pierre
    EUROPEAN HEART JOURNAL, 2007, 28 (10) : 1193 - 1204
  • [36] Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes
    Roe, MT
    Chen, AY
    Riba, AL
    Goswami, RG
    Peacock, WF
    Pollack, CV
    Collins, SP
    Gibler, WB
    Ohman, EM
    Peterson, ED
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12): : 1707 - 1712
  • [37] Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
    Potsis, Thomas Z.
    Katsouras, Christos
    Goudevenos, John A.
    ANGIOLOGY, 2009, 60 (02) : 148 - 158
  • [38] Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes?
    Antzelevitch, Charles
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (05): : 248 - 249
  • [39] Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes
    Gurbel, Paul A.
    Tantry, Udaya S.
    HEART, 2016, 102 (11) : 882 - U101
  • [40] Antiplatelet and antithrombin dose variation in patients with non-ST-segment elevation acute coronary syndromes
    Alexander, KP
    Chen, AY
    T Roe, M
    Newby, LK
    Gibler, WB
    Ohman, EM
    Peterson, ED
    CIRCULATION, 2005, 111 (20) : E312 - E313